Our prostate cancer diagnostic portfolio can give you the confidence you need to improve patient care.
Empower your lab with our portfolio of biomarkers that deliver increased value for men’s health. Our antibodies are pre-diluted and optimized for use on the fully-automated VENTANA BenchMark systems for quality results that are both consistent and reproducible. We continue to develop novel biomarkers with promising utility — such as the EZH2 (SP129) Rabbit Monoclonal Antibody and the Androgen Receptor (SP107) Rabbit Monoclonal Antibody.
ERG (EPR3864) Rabbit Monoclonal Primary Antibody
Developed for high sensitivity and specificity, the ERG (EPR3864) Rabbit Monoclonal Primary Antibody delivers:
VENTANA p63 (4A4) Mouse Monoclonal Primary Antibody
The p63 (4A4) antibody empowers you to make informed, confident decisions.
VENTANA Basal Cell Cocktail 34βE12+p63
Our Basal Cell Cocktail combines p63 (4A4) with 34βE12 to aid in the differentiation of benign and malignant prostatic lesions.
Prostate carcinoma stained with ERG (EPR3864) Rabbit Monoclonal Primary Antibody